OTCM
BIOLQ
Market cap7kUSD
Dec 05, Last price
0.00USD
Name
BIOLASE Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BIOLASE, Inc., along with its various divisions, operates as a global enterprise specializing in the creation, production, distribution, and sale of advanced laser systems. These technologies are specifically designed for dental professionals and their patients across the United States and internationally. The sophisticated laser instruments developed by BIOLASE empower a diverse array of dental specialists—including general dentists, periodontists, endodontists, and oral surgeons—to execute a broad spectrum of minimally invasive procedures. These applications range from cosmetic enhancements and restorative treatments to intricate surgical interventions. Among its core product offerings, the company provides Waterlase all-tissue dental laser systems, which are highly effective for precisely cutting both soft and hard tissues. It also supplies diode soft-tissue laser systems, utilized for procedures involving soft tissue, pain management, teeth whitening, and various other aesthetic treatments. Furthermore, the Epic Hygiene laser assists in addressing non-surgical periodontitis and enhancing overall clinical efficiency. Beyond its primary laser devices, BIOLASE also manufactures and distributes essential consumable items and accessories. This comprehensive range includes flexible fibers, specialized hand pieces, and professional teeth whitening gel kits. The company markets its products through a dedicated in-house sales team and an extensive network of distributors. Established in 1984, the organization was initially known as BIOLASE Technology, Inc., before officially changing its name to BIOLASE, Inc. in 2012. Its corporate headquarters are situated in Foothill Ranch, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||